1/3/2008

Addex Pharmaceuticals SA today announced it is collaborating with U.S.-based Merck & Co. to develop ADX63365, Addex's drug for schizophrenia. The deal grants the Swiss biotech firm $22 million upfront and makes it eligible for up to $680 million in milestone payments.

Full Story:
Reuters

Related Summaries